Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556203 · ClinicalTrials.gov registry record · Phase 3
Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,653
- Enrollment target
NCT02556203 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 1,653 participants.
The verdict
NCT02556203, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,653 participants
- Enrollment target
Study Summary
To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE). To assess the primary bleeding events (PBE) of the rivaroxaban-based strategy compared to an antiplatelet-based strategy, following TAVR.
Interventions
- DRUG Clopidogrel
- DRUG Acetylsalicylic Acid (ASA)
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Vitamin K antagonist (VKA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,653 participants |
| Start Date | 2015-12-16 |
| Est. Completion | 2018-11-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556203
The ClinicalTrials.gov registry entry for NCT02556203 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,653 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Clopidogrel is the first listed.
NCT02556203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02556203 about?
NCT02556203 is a clinical study titled "Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes". To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE). To assess the primary bleeding events (PBE) of the rivaroxaban-based strategy compared to an ant...
What is the current status of trial NCT02556203?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,653 participants. The study started on 2015-12-16. Estimated completion is 2018-11-27.
What interventions are being tested in trial NCT02556203?
The interventions under investigation include: Clopidogrel (DRUG), Acetylsalicylic Acid (ASA) (DRUG), Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Vitamin K antagonist (VKA) (DRUG).
Who is sponsoring clinical trial NCT02556203?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.